AstraZeneca third booster shot ‘strong enough against any Covid variant’

The yet to be published study comes as vaccine makers warn the world will need yearly booster shots or new vaccine to tackle variants, although some scientists question if such shots are necessary.

In this file photo taken on March 24, 2021 a medical worker holds a vial of the AstraZeneca vaccine against Covid-19 at a vaccination hub outside Rome's Termini railway station.
AFP

In this file photo taken on March 24, 2021 a medical worker holds a vial of the AstraZeneca vaccine against Covid-19 at a vaccination hub outside Rome's Termini railway station.

AstraZeneca and Oxford University's Covid-19 vaccine works well as a third booster dose, stepping up antibodies to the coronavirus spike protein among participants, an Oxford study shows, according to the Financial Times.

The news comes as vaccine makers warn that the world will need yearly booster shots, or new vaccines, to tackle virus variants, although some scientists question if such shots are necessary.

READ MORE: AstraZeneca updates US data to show vaccine has 76 percent overall efficacy

Loading...

The newspaper quoted a person familiar with the results of the study as saying it showed the antibody reaction to the booster shot was "strong enough against any variant" and put to rest fears that adenoviruses could not be used more than once.

AstraZeneca and Oxford University did not immediately respond to request for comment on Oxford's yet to be published study.

READ MORE: Can you mix and match Covid-19 vaccines?

Loading...

The vaccine makes use of a new technology employing a modified version of adenoviruses, which cause the common cold, as vectors to ferry instructions to human cells.

This design led to concern among scientists that the doses could lose potency if annual inoculations become necessary to fight new variants.

It is not known when Oxford and AstraZeneca plan to publish study data, the paper added.

The European Union signed a new contract this month for 1.8 billion doses of the Pfizer-BioNTech vaccine to cover booster doses. 

READ MORE: South Korea to resume AstraZeneca vaccines for those aged 30-60

Route 6